US Stock Market Move | Pomegranate Cloud Medicine (POM.US) fell nearly 4% in night trading, while Nasdaq made its debut with a 0.75% increase.

On Thursday, the stock price of the Chinese chronic disease management service online platform Pomegranate Cloud Medical (POM.US) fell during the night session, with the stock dropping by 3.72% to $3.88 by the time of publication. Pomegranate Cloud Medical was listed on the NASDAQ stock exchange on October 8th, with the stock surging nearly 25% at one point during the trading day and closing the IPO first day with a 0.75% increase. The company completed its IPO pricing by issuing 5 million American Depositary Shares (ADS) priced at $4 per share, at the lower end of the $4 to $6 issuance range, raising a total of $20 million in this offering. As of December 31, 2024, the company has signed contracts with over 212,800 doctors, issued over 3 million prescriptions, and has a total of 699,000 transactional patients (patients who have consumed services). In this IPO transaction, Joseph Stone Capital served as the exclusive bookrunner.